Ildong Holdings corrects disclosure on Idience put option contract, names Ildong Pharmaceutical as buyer

• Ildong Holdings filed a corrected disclosure on a put-back option contract tied to Idience’s redeemable convertible preferred share issuance.
• The investor was revised to Ildong Pharmaceutical from the previously disclosed Kiwoom-Yuanta 2019 Scale-up fund group.
• Share subscriptions were updated to 8,000,000 shares at KRW 5,000 each, completed across Nov. 6, 2020, Dec. 14, 2020, Jan. 12, 2021.
• A previously disclosed put-back trigger tied to additional fundraising and pipeline targets by Dec. 31, 2022 was removed.
• The remaining special put-back trigger allows a 50% principal buyback if IPO preliminary review filing missed by Dec. 31, 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ildong Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930000782), on September 30, 2026, and is solely responsible for the information contained therein.